Sign In
Buy FATE
$3.02
-0.0800 (-2.58%)
At Close: Jul 13, 2026
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
08:30am, Thursday, 09'th Jul 2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
04:05pm, Wednesday, 01'st Jul 2026
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripoten
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
06:04am, Wednesday, 24'th Jun 2026
Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the s
Fate Therapeutics Appoints Laura Hamill to Board of Directors
08:30am, Monday, 15'th Jun 2026
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization Accomplished global comm
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
08:30am, Thursday, 04'th Jun 2026
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 02'nd Jun 2026
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent s
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
08:30am, Monday, 01'st Jun 2026
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illus
The $13 Million Company Teaching the Immune System to Hunt Cancer
09:00am, Friday, 29'th May 2026
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
10:40am, Wednesday, 13'th May 2026
Fate Therapeutics (FATE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.32 per share a year ago.
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
08:30am, Wednesday, 13'th May 2026
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to init
Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development t
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st
